Video #1: What to know before you IPO

In the first video of our IPO essentials series, Kevin Morris and Leah Frank of our Capital Markets group highlight what business leaders should be thinking about in leading up to an IPO, including:

  • structuring considerations;
  • due diligence;
  • financial statements; and
  • management and resources.

Watch the next episode of our IPO series on U.S.-Canadian cross-border IPOs.

Click here to visit the main IPO series page.


Leah Frank (00:11): Hi, everyone. Thanks for joining us. We're really looking forward to discussing with you today some key long-lead items that you should be thinking about if you're considering an IPO. I'm Leah Frank. I'm a Partner in our Corporate and Capital Markets Group at Torys.

Kevin Morris (00:25): And I'm Kevin Morris, another Partner in the Capital Markets Group at Torys.

Leah Frank (00:29): So we're going to be talking about four key items today that you should be thinking about upfront. The first is structuring considerations. The second is due diligence. The third is financial statements. And the fourth is management and resources. So in terms of structuring, Kevin—so this will be unique to every company—but what's something that all companies should be thinking about upfront?

Kevin Morris (00:53): Well, I'll start off by talking about the working group for the IPO. Generally, it's five different parties. It's the company which is represented by its management, the company's outside counsel, the company's lawyers, the underwriters—will be the link between the company and its new public investors—the underwriters' counsel, and the company's auditors. And there's also a sixth party who's involved in the IPO planning process, whose interests are part of the whole process, and that's the company's owners. Whether it's a private equity firm or the founder shareholders or another group of investors, the owner's planning is part of the structuring process as well. So at the beginning of the process, it's important that the working group considers any tax planning issues that might arise in the context of the IPO, both for the company and its relationship to its subsidiaries, or its internal capital structure. And the existing shareholders may also have tax planning interests in mind. Another point that the working group needs to consider at the very beginning is, What's the use of proceeds for this IPO? If it's a successful IPO, there'll be millions of dollars raised by public investors. Is that money going to go to the company for it to grow its business? Or is it going to existing shareholders who are going to be exiting their investment? Or it will be a mix of the two? Another question for the working group to consider at the beginning is in many cases, the public being asked to invest in a founder's vision for a new business, to grow the business, and in which case the working group may consider that it wants to ensure that the founder maintains control of the company even after the public invests. And in many cases to enable that to happen, the working group will put in place a dual-class share structure, which means that the founder will get to own shares which have greater voting rights than what the public is going to invest in. So even after the IPO is closed and the company now has public investors, the founder will have enough votes to be able to elect the board for a period going forward. So that's something else the working group needs to consider at the beginning. The key element for the working group to go forward with the IPO is preparing disclosure document, which is called a prospectus, which describes the company and its business, its growth plans, its financial position and its financial history. The working group will be very careful in preparing that document, and they'll do a lot of work to ensure that the disclosure's right and accurate through a process called due diligence. And Leah, I'm going to ask you to speak about that.

Leah Frank (03:23): Sure. So diligence is a very time-consuming process, and there's a lot of work that the company needs to do upfront in order to get ready. We often say to budget about 8 to 16 weeks just to prepare for an IPO. So in terms of diligence, it serves a couple key functions, as Kevin mentioned. The first is that it really ensures the underwriters can understand the business of the company in order to be able to tell its story in the prospectus document and to market the company's shares. The second is that it ensures the working group can make sure all of the material information about the company is included in the prospectus and that nothing material has been omitted. That point is particularly important because the prospectus is a liability document. This means that certain parties including the company, the underwriters, the company's board of directors, among others, bear liability to potential purchasers in the IPO if there's a misrepresentation in the prospectus, which basically means something material is not included or something is materially wrong in the document. And so diligence helps the working group make sure that they're confident that the prospectus is accurate and there's no misrepresentation. In terms of process, there's a lot to do to get ready for diligence. A couple of key questions at the outset: Do have your corporate records up to date? Are they well-organized? What about your material contracts? Are they ready? Are they well organized? What about third party debt, summaries of litigation, employment materials, your closing books for various acquisitions and dispositions? I guess the key point here is to have everything well-organized and available electronically so that it can be quickly put up in a data room for the underwriters and their counsel to review. In terms of the process itself, there's a few different aspects. For example, the underwriters are also going to undertake financial and operational due diligence, and the operational diligence will depend on the business of the company, but likely there will be some sense of site visits or diligence of physical assets. They'll also call your key customers and suppliers. So just be thinking about that and how that's going to fit into the overall process of the IPO. There will also be a factual circle-up exercise on the prospectus. Essentially, every statement in the prospectus needs to be backed up. So if you say you're the third largest producers of widgets in Canada, the underwriters are going to want to see evidence to back up that statement. Finally, there will be an auditor comfort process where the underwriters are looking to the auditors of your company to provide backup for the statements in the prospectus that derive from the financial statements to confirm that these numbers are correctly presented and calculated. And again, that's just another process that's time consuming and it requires management attention. So on the topic of auditors and financial statements, do you want to talk about what's required for an IPO?

Kevin Morris (06:27): Sure. And I will say at the beginning that when we talk about a timeline for the IPO, it's often that the preparation of financial statements is the key gating item—from the start, to when you get to file the prospectus to go public. The preparation of financial statements can often take the most time. There's very little room to maneuver. The statutory requirements are that the company needs to include three years of audited financial statements in the prospectus. Those financial statements need to be audited in accordance with what's called IFRS, the International Financial Reporting Standards. They need to be audited in accordance with Canadian public company standards, and there's very little room to maneuver from that requirement. Another key term that the working group needs to be aware of at the very beginning of the planning is the term "significant acquisition". Has the company made what's called a significant acquisition over the past three years, and that's a defined term under the securities legislation. If the company has made such an acquisition, then the prospectus will need to include financial statements of what they've acquired. And often, that could be a key indicating as well. So it's something that the working group needs to look into at the very beginning. In addition to the audited financial statements, the prospectus needs to include unaudited financial statements, or the most recent interim period prior to filing the prospectus. So it'll be the most recent quarter and those statements don't need to be audited. And one last note on the financial statements, the prospectus must also include what's called "management's discussion and analysis of financial results" for all of the financial periods for which there are financial statements in the prospectus. That's something that management's going to have to pay attention to and it'll take a part of their time. And Leah, actually, that leads me to ask you the question about management's involvement and what has to happen with management during this whole process.

Leah Frank (08:18): Sure. So that's a key thing to think about upfront. The make up of your management and your board of directors—is this the right group for a public company? Are they IPO-ready? The other question is, who are your named executive officers going to be or your NEOs? These are five individuals: The CEO, CFO and the three most highly compensated executive officers. They're going to be named every year in your management information circular and all details of their compensation are going to be publicly available. In terms of the board, you'll need to consider the various securities law and TSX requirements. Do your directors have the right qualifications and public company experience? You're going to need a majority of independent directors at the company. For example, the CEO is often on the board and he or she won't be independent of the company. Do you have three financially-literate directors to serve on the audit committee? Is your board sufficiently diverse or gender-diverse? Annually you're going to need to include disclosure of diversity of your board and the executive officers in your management information circular that's publicly available. And another note on the board, the TSX will be doing background checks on your proposed board of directors, so just keep that in mind. And finally, the last point I'd make is really a practical one that Kevin alluded to, which is consider whether your management team, the key members of management, have sufficient time and resources to dedicate to this IPO process in addition to their day-to-day jobs. So that's all the time we have for today! Thank you for joining us. Look forward to more videos from us on other aspects of the IPO process, both in Canada and the US. Thank you.

Kevin Morris (10:00): Thank you.

Le mois dernier, le Canada a publié sa première Stratégie industrielle de défense (la Stratégie), qui souligne l’engagement du Canada à développer une base industrielle de défense solide et à stimuler la croissance économique. Ces efforts pourraient aussi comprendre le renforcement de l’état de préparation à la biodéfense et aux contre-mesures médicales, ce qui pourrait constituer des débouchés pour le secteur canadien des sciences de la vie en raison de l’importance accordée aux capacités nationales en ce sens et de la nécessité d’atténuer les risques d’urgences sanitaires.

Développement de contre-mesures médicales au Canada

Comme indiqué dans les bulletins précédents, le quatrième pilier de la Stratégie est axé sur la « sécurisation des chaînes d’approvisionnement pour les intrants et les biens clés » par le renforcement de la production nationale et le stockage de ressources. L’accent est mis tout particulièrement sur les contre-mesures médicales, en précisant que nos « alliés ont établi un lien explicite entre l’état de préparation à la biodéfense et aux contre-mesures médicales et leur sécurité économique et nationale, en élaborant de nouvelles stratégies et de nouveaux mécanismes pour faire progresser ces travaux ». Les contre-mesures médicales désignent divers produits réglementés pouvant être utilisés pour protéger la population lors d’une situation d’urgence de grande ampleur, comme l’éclosion d’une maladie ou une attaque impliquant des armes chimiques, biologiques ou nucléaires. Il peut s’agir de vaccins, de médicaments thérapeutiques et produits biologiques, de dispositifs de tests diagnostiques, des équipements de protection individuelle ou industrielle, et d’autres dispositifs médicaux. Les contre-mesures médicales sont essentielles à la réduction et à l’atténuation des dommages lors d’une urgence de santé publique.

Exploiter les voies réglementaires mises en place lors de la pandémie de COVID-19

Pendant et après la pandémie de COVID-19, le Canada a mis en place plusieurs nouvelles voies réglementaires comme mécanismes d’accélération des approbations de produits médicaux, ce qui pourrait offrir au gouvernement des options pour déployer des contre-mesures médicales afin de faire face aux risques pour la santé publique. Au début de la pandémie, Santé Canada a émis diverses ordonnances provisoires pour permettre l’importation et la vente de médicaments et de dispositifs médicaux qui n’avaient pas eu l’approbation des voies réglementaires traditionnelles. Or, Santé Canada a plutôt fait confiance aux voies d’approbation réglementaire et de l’exemption de certaines exigences en homologation de produits des pays impliqués dans la transaction. Beaucoup de ces règles provisoires ont depuis été officiellement intégrées à la réglementation en vertu de la Loi sur les aliments et drogues et ont été appliquées bien après la COVID-19. Conformément au Règlement sur les aliments et drogues, Santé Canada tient à jour la Liste des maladies qui menacent la santé publique et utilisera une procédure d’autorisation modifiée pour les médicaments d’urgence de santé publique pouvant traiter les affections figurant sur la liste. De même, le Règlement sur les instruments médicaux a établi une liste d’instruments médicaux répondant à un besoin urgent de santé publique, ce qui permet à Santé Canada d’autoriser la commercialisation de ces instruments de manière accélérée. Ces outils réglementaires sont utilisés automatiquement quand une situation médicale présente un grand risque pour la santé publique au Canada et nécessite une action immédiate pour contrer ce risque.

Le rôle de la Stratégie dans le renforcement du régime réglementaire de la santé au Canada

La stratégie prévoit que le Canada adoptera une approche proactive en matière de planification en amont des crises sanitaires. Le gouvernement entend s’assurer que les produits médicaux sont déjà disponibles au Canada afin qu’ils puissent être distribués rapidement en cas d’urgence. D’autres modifications récentes au Règlement sur les aliments et drogues permettent de prépositionner au Canada tous les médicaments d’urgence en santé publique, ce qui signifie qu’ils peuvent être importés dans des installations d’entreposage canadiennes avant que leur mise sur le marché n’ait été autorisée. La Stratégie s’appuie sur ces fondements, en faisant référence à l’organisme existant Préparation aux crises sanitaires Canada (PCSC), un organisme opérationnel spécial au sein d’Innovation, Sciences et Développement économique Canada (ISDE), et à un nouveau Fonds des sciences de la vie, lesquels « collaborent avec des partenaires internationaux et de soutenir l’élaboration et la production de contre-mesures médicales ». PCSC supervise la Stratégie en matière de biofabrication et de sciences de la vie du Canada, qui vise à développer un secteur national des sciences de la vie fort et compétitif doté de capacités de biofabrication de pointe, en mettant l’accent sur la capacité à se préparer et à faire face aux futures priorités et crises sanitaires. Dans cette optique, il y aura des occasions pour les fabricants de nouer des collaborations de recherche et des accords commerciaux ou d’approvisionnement liés aux contre-mesures médicales financées par des programmes fédéraux.

Étroitement lié aux capacités nationales, le pilier III de la stratégie implique « Investissement ciblé pour renforcer un secteur canadien de la défense novateur », avec la promesse que le gouvernement fédéral « soutiendr[a] la recherche et le développement, protéger[a] la propriété intellectuelle, soutiendr[a] les petites et moyennes entreprises, investir[a] dans les compétences et la formation, et encourager[a] les exportations afin de créer un secteur de la défense agile et concurrentiel à l’échelle mondiale ». La nécessité de favoriser le développement de la propriété intellectuelle (PI) et la conservation des droits du Canada est mentionnée à plusieurs reprises dans la Stratégie. Par exemple, la Stratégie prévoit l’établissement de partenariats officiels avec l’industrie canadienne qui « [assureront] la propriété et le contrôle nationaux de la propriété intellectuelle (PI) et des capacités essentielles. » La Stratégie reconnaît l’immense talent des établissements canadiens et la précieuse recherche qui y est menée actuellement et qui est déjà financée par des subventions de recherche d’organismes tels que le Conseil de recherches en sciences naturelles et en génie et les Instituts de recherche en santé du Canada, et fait aussi référence à l’engagement de 1,6 milliard de dollars pour de nouveaux fonds de recherche dans le budget de 2025. Cette prise de conscience de la nécessité de promouvoir et de soutenir l’innovation au Canada laisse présager des possibilités de financement, notamment dans les domaines où le Canada accuse un retard en matière de production nationale et où des engagements d’investissement et de fabrication au Canada peuvent être pris.

Prochaines étapes

Dans les prochains mois, nous prévoyons que le gouvernement du Canada publiera d’autres directives et des mesures de suivi. L’équipe de défense des conservateurs poursuivra sa couverture de perspectives sur la défense au Canada en publiant une analyse supplémentaire pour donner des précisions sur l’incidence de la Stratégie sur de multiples secteurs.

Inscrivez-vous pour recevoir les dernières nouvelles

Restez à l’affût des nouvelles d’intérêt, des commentaires, des mises à jour et des publications de Torys.

Inscrivez-vous maintenant